Search Results - Barry A. Singer
- Showing 1 - 7 results of 7
-
1
-
2
-
3
-
4
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study by Tjalf Ziemssen, Ann D. Bass, Bart Van Wijmeersch, Sara Eichau, Stephan Richter, Frank Hoffmann, Nicole M. Armstrong, Magdalena Chirieac, Janete Cunha-Santos, Barry A. Singer
Published in Therapeutic Advances in Neurological Disorders (2025-02-01)Get full text
Article -
5
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, doub... by Annette Wundes, Sibyl Wray, Ralf Gold, Barry A. Singer, Elzbieta Jasinska, Tjalf Ziemssen, Jerome de Seze, Pavle Repovic, Hailu Chen, Jerome Hanna, Jordan Messer, Catherine Miller, Robert T. Naismith
Published in Therapeutic Advances in Neurological Disorders (2021-03-01)Get full text
Article -
6
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study by Barry A. Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P. Mendoza, James B. Lewin, Sai L. Shankar
Published in Neurology and Therapy (2024-06-01)Get full text
Article -
7
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study by Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, Xavier Montalban
Published in Therapeutic Advances in Neurological Disorders (2023-09-01)Get full text
Article